[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"high-cholesterol\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:high-cholesterol":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,42,73,101,132],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100619673","phase-1-phase-1a-study-to-evaluate-the-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-rn5681-in-healthy-volunteers-100619673",false,"NCT07347678","Phase 1a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RN5681 in Healthy Volunteers","A Phase 1a, Randomized, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RN5681 in Healthy Volunteers","Inclusion Criteria:\n\n* Body mass index (BMI) 18 to 35 kg\u002Fm2\n* Fasting LDL-C ≥70 mg\u002FdL (1.81 mmol\u002FL) (all SAD cohorts); fasting LDL-C ≥100 mg\u002FdL (2.59 mmol\u002FL) (POC cohort only)\n* Lp(a) at Screening: SAD cohort: ≥25 nmol\u002FL POC cohort: ≥100 nmol\u002FL\n* Fasting triglycerides \\\u003C400 mg\u002FdL (4.51 mmol\u002FL) at Screening\n* No clinically significant abnormalities of hepatic or renal function\n\nExclusion Criteria:\n\n* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>1.5× the upper limit of normal at screening\n* Hemoglobin A1c (HbA1c) ≥6.5% at screening\n* Current regular smoker (defined as \\>2 cigarettes\u002Fday or \\>10 cigarettes\u002Fweek) within 3 months prior to screening\n* Use of any siRNA, antisense oligonucleotide (ASO), cell and gene therapy, or clustered regularly interspaced short palindromic repeats (CRISPR) agent in the prior 12 months\n* Received any prescription lipid-lowering medication, including but not limited to statins, ezetimibe, and PCSK9 inhibitors to alter serum lipids within 30 days before screening",true,"ALL","18 Years","65 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of single doses of RN5681 in Adult healthy subjects",[28],"High Cholesterol","RECRUITING","2026-03-30",{"date":32,"type":33},"2026-04-03","ACTUAL",{"date":35,"type":33},"2026-03-12",{"date":37,"type":22},"2027-07",{"name":39,"class":40},"Ikaria Bioscience Pty Ltd","INDUSTRY",2,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":4},"100622045","cobas-lumira-collection-of-venous-and-capillary-blood-samples-for-the-research-optimization-and-calibration-of-new-diagnostic-devices-100622045","NCT07378514","Cobas® Lumira Collection of Venous and Capillary Blood Samples for the Research, Optimization and Calibration of New Diagnostic Devices","Cobas® Lumira Collection of Venous and Capillary Blood Samples for the Research, Optimization and Calibration of New Diagnostic Devices (EVOLVE)","EVOLVE","Inclusion Criteria:\n\n1. Willing and able to provide written informed consent.\n2. Willing to comply with study procedures.\n3. The participant must present as one of the following cohorts (primary presenting condition):\n\n   * Cohort A - Embolism Cohort (participants presenting with symptoms indicative of thromboembolic events)\n   * Cohort B - Infection or Inflammation Cohort (participants presenting with symptoms indicative of infection or inflammatory disorders)\n   * Cohort C - Cardiovascular Cohort (participants presenting with symptoms indicative of heart failure or acute coronary syndrome)\n   * Cohort D - Renal Cohort (participants presenting with symptoms indicative of renal disorders)\n   * Cohort E - Oral Anticoagulation Cohort (participants with ongoing vitamin K antagonist therapy for at least four weeks)\n   * Cohort F - Diabetes Cohort (participants with suspected pre-Diabetes or diagnosed with Diabetes Mellitus Type 1 or Type 2)\n   * Cohort G - Lipid Cohort (participants presenting with symptoms indicative for Hypercholesterolemia )\n   * Cohort H - Liver Cohort (participants with symptoms indicative of hepatic disorders).\n\nInclusion Criteria for Cohorts A, B, C, D, E, G, and H:\n\n1\\. Participants ≥ 18 years of age\n\nInclusion Criteria for Cohort F (Diabetes Cohort):\n\n1\\. Participants ≥ 16 years old\n\nExclusion Criteria:\n\n1. Subjects deemed inappropriate for the study by the Principal Investigator.\n2. Participants who have previously been enrolled in the EVOLVE study in the past 60 days.\n\nExclusion Criteria for Cohort E (Oral Anticoagulation Cohort):\n\n1. Subjects who are currently taking non-vitamin K antagonist oral anticoagulants (NOACs) including but not limited to apixaban, dabigatran etexilate, edoxaban and rivaroxaban.\n2. Subjects who have anti-phospholipid antibody syndrome (APS)\n3. The participant is currently receiving or has received within the past thirty (30) days of the study visit an experimental biologic, experimental drug, or experimental device including either treatment or therapy.","16 Years",{"count":52,"type":22},30000,"OBSERVATIONAL","This study is a blood sample collection study, collecting venous and capillary blood samples from adult patients in the UK, with a range of health conditions. The purpose of this study is to collect blood samples to help develop, improve, and fine-tune new and existing diagnostic tests for the cobas® lumira instrument. This instrument is a diagnostic medical device with single-use test strips, that allows diagnostic testing right at the patient's side. The aim is to improve doctors' ability to monitor health conditions more quickly and easily.\n\nApproximately 30,000 patients are expected to participate in this study, across multiple UK sites.",[56,57,58,59,60,61,28,62],"Blood Clots","Infection and Inflammatory Reaction","Heart Disease","Kidney Disease","Vitamin K Antagonist","Diabetes","Liver Disease","NOT_YET_RECRUITING","2026-01-22",{"date":66,"type":33},"2026-01-30",{"date":68,"type":22},"2026-04",{"date":70,"type":22},"2031-07",{"name":72,"class":40},"LumiraDx UK Limited",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":79,"minAge":18,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":100},"100609871","fellaship-to-better-health-100609871","NCT07220213","FELLAShip to Better Health","Inclusion Criteria:\n\n* Self-identified Black men\n* Age 18 or older\n* LE8 (Life's Essential 8) score (threshold not specified, but implies \"less than ideal\" CVH)\n* English speaking\n* Resides in the Metropolitan Birmingham, Alabama area\n* No physical activity restrictions imposed by a healthcare provider\n\nExclusion Criteria:\n\n* Not identifying as Black and male\n* Under age 18\n* Non-English speakers\n* Not living in the Birmingham, Alabama metro area\n* Having a healthcare provider-imposed restriction on physical activity\n* Ideal CVH (i.e., LE8 (Life's Essential 8) score above inclusion threshold)","MALE",{"count":81,"type":22},90,[83],"NA","The goal of this clinical trial is to evaluate the implementation and effectiveness of the FELLAship program-a church-based cardiovascular health (CVH) intervention-in Black men aged 35-70 who are at risk for heart disease, diabetes, obesity, and related conditions. The main questions this study aims to answer are:\n\n* Does participation in the FELLAship program improve cardiovascular health metrics (e.g., blood pressure, cholesterol, blood sugar) and health behaviors among Black men at The Worship Center Christian Church (TWC)?\n* What factors influence the adoption, delivery, and sustainability of the FELLAship program in a faith-based setting? Researchers will compare an immediate-start intervention group and a delayed-start (waitlist control) group to assess both short-term health outcomes and program implementation factors.\n\nParticipants will:\n\n* Attend a 90-minute weekly session for 24 weeks, including 45 minutes of physical activity led by a certified trainer and 45 minutes of health education delivered by trained coaches.\n* Receive one-on-one support from a community health worker to reduce barriers to care and engage with primary care.\n* Complete biometric health screenings and surveys at baseline, 12 weeks, and 24 weeks to assess clinical and behavioral outcomes.\n* Use a smartwatch, blood pressure cuff, and other tools to track progress in real time.\n* Participate in exit focus groups or interviews to share feedback about the intervention.\n* A subset of TWC leaders and interventionists (N=15) will also be interviewed to assess implementation, resource needs, and sustainability.\n\nThis study uses the RE-AIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance) framework to assess Reach, Effectiveness, Adoption, Implementation, and Maintenance, and aims to inform scalable strategies for improving CVH among Black men in trusted community settings.",[86,28,87,88,89,90],"High Blood Glucose","High Cholesterol\u002FHyperlipidemia","Blood Sugar; High","Obesity & Overweight","Diabetes Type 2","2026-01-21",{"date":64,"type":33},{"date":94,"type":33},"2026-01-01",{"date":96,"type":22},"2027-01-01",{"name":98,"class":99},"University of Alabama at Birmingham","OTHER",1,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":23,"phases":112,"briefSummary":113,"conditions":114,"keywords":118,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":100},"100602674","healthy-living-anson-study-100602674","NCT07126587","Healthy Living Anson Study","Healthy Living Anson","HLA","Inclusion Criteria:\n\n* Potential participants must be a resident of Anson County.\n* At least 18 years of age.\n* Have or be at risk for a chronic disease.\n* Ability to make own dietary decisions.\n* Ability to travel to a central Anson County location for data collection and group class sessions.\n* Ability and willingness to try the prepared meals.\n* Ability to store 10 frozen meals in a freezer.\n* Ability to communicate in English\n* No dietary restrictions or food allergies such that a Mediterranean diet is not appropriate.","99 Years",{"count":111,"type":22},120,[83],"The goal of this randomized delayed control intervention research study is to see if participants who receive education and healthy prepared meals improve the quality of their diet compared to participants who receive only physical activity education and coaching.",[115,90,58,116,117,28],"Obesity (Disorder)","Hypertension","Cancer",[106,119,120,121,122],"HLA study","nutrition","healthy eating","overweight (BMI ≥ 25)","2025-10-29",{"date":125,"type":33},"2025-10-30",{"date":127,"type":33},"2025-09-24",{"date":129,"type":22},"2028-03-30",{"name":131,"class":99},"University of North Carolina, Chapel Hill",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":100},"100530858","complete-lifestyle-medicine-intervention-program-100530858","NCT06192251","Complete Lifestyle Medicine Intervention Program","Complete Lifestyle Medicine Intervention Program (CLIP)","CLIP","Inclusion Criteria:\n\n* prediabetes,\n* type 2 diabetes,\n* pre-hypertension,\n* systemic hypertension,\n* heart disease, dyslipidemia,\n* and\u002For excess weight (BMI ≥ 25 (42)).\n\nExclusion Criteria:\n\n* Healthy participants",{"count":141,"type":22},8,"This project will use a mixed design and will be conducted at the West Parry Sound Health Centre. Based on similar studies there is an expected 10% drop-out rate so 20 participants per group will be invited to aim to have 15 finish. Total participants invited over the two-year study will be 40. The participants will be followed over a Complete 6-month Lifestyle medicine Intervention Program (CLIP) involving a collaboration between physicians, health coach, registered dietitians, and kinesiology. The CLIP will cover the 6 pillars of lifestyle medicine in 12-14 fundamentals of lifestyle medicine group classes.",[28,61,144,116,145],"Obesity","Heart Diseases","2024-01-04",{"date":148,"type":33},"2024-01-08",{"date":150,"type":33},"2023-11-06",{"date":152,"type":22},"2026-11-06",{"name":154,"class":99},"Northern Ontario School of Medicine"]